Cargando…

Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study

AIMS/INTRODUCTION: Liraglutide and empagliflozin suppress cardiovascular events. However, reports on their long‐term combined use with insulin therapy or direct comparisons of these drugs are limited. MATERIALS AND METHODS: This open‐label, parallel‐group, randomized controlled trial compared the ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakaguchi, Hirotatsu, Kondo, Yoshinobu, Kyohara, Mayu, Konishi, Hiromi, Oiwa, Koji, Terauchi, Yasuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610130/ https://www.ncbi.nlm.nih.gov/pubmed/32279451 http://dx.doi.org/10.1111/jdi.13270

Ejemplares similares

Comparison of the effects of empagliflozin and glimepiride on endothelial function in patients with type 2 diabetes: A randomized controlled study
por: Tamura, Haruka, et al.
Publicado: (2022)

The Roles of the IGF Axis in the Regulation of the Metabolism: Interaction and Difference between Insulin Receptor Signaling and IGF-I Receptor Signaling
por: Okuyama, Tomoko, et al.
Publicado: (2021)

Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes
por: Kondo, Yoshinobu, et al.
Publicado: (2013)

Influence of Timing of Insulin Initiation on Long-term Glycemic Control in Japanese Patients with Type 2 Diabetes: A Retrospective Cohort Study
por: Miyazaki, Takashi, et al.
Publicado: (2019)

Soluble EGFR, a hepatokine, and adipsin, an adipokine, are biomarkers correlated with distinct aspects of insulin resistance in type 2 diabetes subjects
por: Kyohara, Mayu, et al.
Publicado: (2020)

Metabolic recovery of lipodystrophy, liver steatosis, and pancreatic β cell proliferation after the withdrawal of OSI-906
por: Tajima, Kazuki, et al.
Publicado: (2017)

Association between circulating SerpinB1 levels and insulin sensitivity in Japanese with type 2 diabetes: A single-center, cross-sectional, observational study
por: Kyohara, Mayu, et al.
Publicado: (2022)

Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin
por: Ahmann, Andrew
Publicado: (2015)

Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats
por: Trang, Nguyen Ngoc, et al.
Publicado: (2021)

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
por: Iijima, Takahiro, et al.
Publicado: (2023)

Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study
por: Terauchi, Yasuo, et al.
Publicado: (2019)

Efficacy and safety of liraglutide added to insulin therapy in elderly patients with type 2 diabetes
por: Tonoike, Mie, et al.
Publicado: (2018)

Identification of the matricellular protein Fibulin-5 as a target molecule of glucokinase-mediated calcineurin/NFAT signaling in pancreatic islets
por: Okuyama, Tomoko, et al.
Publicado: (2017)

Cost‐effectiveness of second‐line empagliflozin versus liraglutide for type 2 diabetes in the United States
por: Reifsnider, Odette S., et al.
Publicado: (2022)

Association of the plasma xanthine oxidoreductase activity with the metabolic parameters and vascular complications in patients with type 2 diabetes
por: Okuyama, Tomoko, et al.
Publicado: (2021)

A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg
por: Seino, Yutaka, et al.
Publicado: (2022)

Comparison of Lipid-Lowering Effects of Anagliptin and Miglitol in Patients With Type 2 Diabetes: A Randomized Trial
por: Iijima, Takahiro, et al.
Publicado: (2020)

The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
por: Ehlers, Lars Holger, et al.
Publicado: (2021)

Is a Switch From Insulin Therapy to Liraglutide Possible in Japanese Type 2 Diabetes Mellitus Patients?
por: Kawata, Takehiro, et al.
Publicado: (2014)

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial
por: Rosenstock, J., et al.
Publicado: (2015)

Comparison of Azelnidipine and Trichlormethiazide in Japanese Type 2 Diabetic Patients with Hypertension: The COAT Randomized Controlled Trial
por: Takihata, Masahiro, et al.
Publicado: (2015)

Asymptomatic meningitis diagnosed by positron emission tomography in a patient with syndrome of inappropriate antidiuretic hormone secretion: a case report
por: Hasebe, Masanori, et al.
Publicado: (2021)

Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin‐secreting capacity
por: Kozawa, Junji, et al.
Publicado: (2012)

Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics
por: Htoo, Phyo T., et al.
Publicado: (2022)

Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3)
por: Dahlqvist, Sofia, et al.
Publicado: (2018)

Abdominal aortic calcification is associated with Fibrosis‐4 index and low body mass index in type 2 diabetes patients: A retrospective cross‐sectional study
por: Togashi, Yu, et al.
Publicado: (2022)

Comparison of Glucose Control by Added Liraglutide to Only Insulin Infusion in Diabetic Patient Undergoing Cardiac Surgery: A Preliminary Randomized-Controlled Trial
por: Sindhvananda, Wacharin, et al.
Publicado: (2023)

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo‐controlled trial
por: Ahmann, A., et al.
Publicado: (2015)

Evaluation of the appropriateness of using glucometers for measuring the blood glucose levels in mice
por: Togashi, Yu, et al.
Publicado: (2016)

Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
por: Gough, Stephen CL, et al.
Publicado: (2016)

The efficacy and safety of liraglutide added to metformin in patients with diabetes: a meta-analysis of randomized controlled trials
por: Gu, Jianqiu, et al.
Publicado: (2016)

Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance
por: Hattori, Sachiko
Publicado: (2018)

Empagliflozin in type 1 diabetes
por: Mathieu, Chantal, et al.
Publicado: (2019)

The Effects of Ramelteon on Glucose Metabolism and Sleep Quality in Type 2 Diabetic Patients With Insomnia: A Pilot Prospective Randomized Controlled Trial
por: Tsunoda, Tetsuji, et al.
Publicado: (2016)

Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the DUAL IV trial
por: Rodbard, H. W., et al.
Publicado: (2016)

Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)
por: Lind, Marcus, et al.
Publicado: (2015)

A Randomized Controlled Trial of a Mini Low-Carbohydrate Diet and an Energy-Controlled Diet Among Japanese Patients With Type 2 Diabetes
por: Kimura, Masayo, et al.
Publicado: (2018)

Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutide
por: Minze, Molly G, et al.
Publicado: (2016)

Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus
por: Mader, Julia K., et al.
Publicado: (2016)

Retrospective Analysis of an Insulin-to-Liraglutide Switch in Patients with Type 2 Diabetes Mellitus
por: Bruinstroop, Eveline, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mg9n93pfkc0l0vuivmiqc39qu9